Announcements
- ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates
- ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
- ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
- ORIC Pharmaceuticals Announces $125 Million Private Placement Financing
- ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones
- ORIC Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
More ▼
Key statistics
On Thursday, Oric Pharmaceuticals Inc (4TZ:DEU) closed at 12.50, -17.76% below its 52-week high of 15.20, set on Mar 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 12.50 |
---|---|
High | 12.90 |
Low | 12.30 |
Bid | 12.40 |
Offer | 12.50 |
Previous close | 12.50 |
Average volume | 104.60 |
---|---|
Shares outstanding | 67.38m |
Free float | 60.96m |
P/E (TTM) | -- |
Market cap | 907.22m USD |
EPS (TTM) | -1.97 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 20:44 BST.
More ▼